dc.creatorBarrio, Daniel Alejandro
dc.creatorEtcheverry, Susana Beatriz
dc.date.accessioned2021-01-27T16:47:37Z
dc.date.accessioned2022-10-15T00:49:37Z
dc.date.available2021-01-27T16:47:37Z
dc.date.available2022-10-15T00:49:37Z
dc.date.created2021-01-27T16:47:37Z
dc.date.issued2010-11
dc.identifierBarrio, Daniel Alejandro; Etcheverry, Susana Beatriz; Potential use of vanadium compounds on therapeutics; Bentham Science Publishers; Current Medicinal Chemistry; 17; 11-2010; 3632-3642
dc.identifier0929-8673
dc.identifierhttp://hdl.handle.net/11336/123905
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4326655
dc.description.abstractVanadium is a trace element present in practically all cells in plants and animals. While the essentiality of vanadium for human beings remains to be well established, vanadium has become an increasingly important environmental metal. Vanadium compounds exert a variety of biological activities and responses. At pharmacological doses, vanadium compounds display relevant biological actions such as insulin and growth factor mimetic or enhancing effects, as well as osteogenic and cardioprotective activity. On the other hand, depending on the nature of compounds and their concentrations, toxicological actions and adverse side effects may also be shown. Nevertheless, the toxic effects may be useful to develop new antitumoral drugs. In this review, the authors summarize current knowledge and new advances on in vitro and in vivo effects of inorganic and organically-chelated vanadium compounds. The effects of vanadium derivatives on some cellular signaling pathways related to different diseases are compiled. In particular, the pathways relevant to the insulin mimetic, osteogenic, cadioprotective and antitumoral actions of vanadium compounds have been comprehensively reviewed. The knowledge of these intracellular signaling pathways may facilitate the rational design of new vanadium compounds with promising therapeutic applications as well as the understanding of secondary side effects derived from the use of vanadium as a therapeutic agent.
dc.languageeng
dc.publisherBentham Science Publishers
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2174/092986710793213805
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://pubmed.ncbi.nlm.nih.gov/20846114/
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/72554/article
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectVanadium cimpounds
dc.subjectInsulinmimics
dc.subjectAntitumoral
dc.subjectOsteogenic
dc.titlePotential use of vanadium compounds on therapeutics
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución